Boosting hopes for a wider label than previously thought, Dendreon Corp. released final three-year follow-up data from a Phase III study of Provenge. (BioWorld Today)
Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)
Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)
